Natural History of GACI With or Without ARHR2 or PXE

The Natural History of Generalized Arterial Calcification of Infancy (GACI) With or Without Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2) or Pseudoxanthoma Elasticum (PXE)

Sponsors

Lead Sponsor: Westfälische Wilhelms-Universität Münster

Collaborator: ICON plc

Source Westfälische Wilhelms-Universität Münster
Brief Summary

Generalized arterial calcification of infancy (GACI) is an ultra-rare disorder with an estimated birth prevalence of around 1 in 400,000.1 GACI is generally fatal before birth or within the first six months after birth. The cause of death is frequently myocardial infarction or stroke. GACI is strongly associated with inactivating mutations in ectonucleotide pyrophosphate/ phosphodiesterase 1 (ENPP1). Many patients with GACI, including some without an ENPP1 mutation also present with mutations in adenosine triphosphate binding cassette transporter protein subfamily C member 6 (ABCC6). Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) and pseudoxanthoma elasticum (PXE) are believed to be closely related to GACI. ARHR2 is caused by mutations in the ENPP1 gene and PXE is caused by mutations in the ABCC6 gene, with both being observed among patients with GACI. The natural history of GACI and in particular its long term morbidity and mortality are poorly understood. The primary objective of this study is to characterize overall survival among patients with GACI, over time from birth.

Detailed Description

Background: Generalized arterial calcification of infancy (GACI) is an ultra-rare disorder with an estimated birth prevalence of around 1 in 400,000.1 GACI is characterized by extensive arterial calcifications, arterial stenosis, myointimal proliferation and periarticular calcifications. Individuals with GACI also experience calcification in other body areas, such as joints and organs. GACI is generally fatal before birth or within the first six months after birth. The cause of death is frequently myocardial infarction or stroke. GACI is strongly associated with inactivating mutations in ectonucleotide pyrophosphate/ phosphodiesterase 1 (ENPP1); around three quarters of GACI cases investigated had one or several ENPP1 mutations. Many patients with GACI, including some without an ENPP1 mutation also present with mutations in adenosine triphosphate binding cassette transporter protein subfamily C member 6 (ABCC6). Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) and pseudoxanthoma elasticum (PXE) are believed to be closely related to GACI. ARHR2 is caused by mutations in the ENPP1 gene5 and PXE is caused by mutations in the ABCC6 gene,3 with both being observed among patients with GACI. The natural history of GACI and in particular its long term morbidity and mortality are poorly understood, but a strong understanding of the condition will be crucial for further therapy development and drug testing. This study aims to address this knowledge gap. Objectives: The primary objective of this study is to characterize overall survival among patients with GACI, over time from birth. Secondary objectives are to: - Characterize the patient and disease characteristics; - Describe symptomology at diagnosis and the change in symptomology over time; - Describe treatment patterns specific to GACI or rickets - Characterize mental/physical impairment, education, and employment situation; - Characterize the sequelae of the disease; - Prevalence of rickets; and - Growth velocities. Eligibility: - GACI genotype (mutation in ENPP1 and/or ABCC6) confirmed through mutational analysis of the patient and a GACI phenotype confirmed by imaging or biopsy; or - GACI phenotype confirmed with imaging, biopsy, or mutational analysis of the parents indicating a GACI genotype (mutation in ENPP1 and/or ABCC6) coinciding with symptoms of the patient. Data will be collected for both living and deceased patients Design: Retrospective multicenter chart review

Overall Status Unknown status
Start Date 2018-03-15
Completion Date 2019-12-31
Primary Completion Date 2019-12-31
Study Type Observational
Primary Outcome
Measure Time Frame
Survival Recruitment for this study will end in March 2019
Enrollment 80
Condition
Intervention

Intervention Type: Other

Intervention Name: No intervention

Description: This is a retrospective chart review study.

Eligibility

Sampling Method:

Non-Probability Sample

Criteria:

Inclusion Criteria: - GACI genotype (mutation in ENPP1 and/or ABCC6) confirmed through mutational analysis of the patient and a GACI phenotype confirmed by imaging or biopsy; or - GACI phenotype confirmed with imaging, biopsy, or mutational analysis of the parents indicating a GACI genotype (mutation in ENPP1 and/or ABCC6) coinciding with symptoms of the patient. - Data will be collected for both living and deceased patients Exclusion Criteria: - Caregivers are not able to give written consent.

Gender:

All

Minimum Age:

N/A

Maximum Age:

N/A

Overall Official
Last Name Role Affiliation
Frank Rutsch, MD Principal Investigator WWU Munster
Overall Contact Contact information is only displayed when the study is recruiting subjects.
Location
Facility: Status: Contact: WWU Munster Frank Rutsch, MD +492518347700 [email protected]
Location Countries

Germany

Verification Date

2018-11-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Westfälische Wilhelms-Universität Münster

Investigator Full Name: Frank Rutsch

Investigator Title: Prof. Dr. Frank Rutsch, MD

Has Expanded Access No
Condition Browse
Patient Data No
Study Design Info

Observational Model: Cohort

Time Perspective: Retrospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Generalized Arterial Calcification in Infancy

Clinical Trials on No intervention